Status:
COMPLETED
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma
Lead Sponsor:
Swedish Orphan Biovitrum
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study was to evaluate the efficacy and effect of palifermin on the incidence of oral mucositis in subjects with multiple myeloma receiving Melphalan followed by autologous peripher...
Detailed Description
This was a double-blind, placebo-controlled, randomized, multicenter Phase IIIb study of palifermin given before and after dose chemotherapy (total 6 doses) or before dose chemotherapy only (total 3 d...
Eligibility Criteria
Inclusion
- Multiple myeloma (MM) subjects scheduled to receive high-dose Melphalan in a one day schedule followed by autologous peripheral blood progenitor cell (PBSCT)
- Body Mass Index (BMI) ≤ 35
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, or an ECOG status of 3 if the reason for a status of 3 is exclusively due to MM (e.g. pathological fracture)
- Functional hematopoietic, hepato-renal and pulmonary systems
- Subjects at minimum with a baseline best corrected visual acuity (BCVA) of 20/40, (6/12 or 0.5 on the decimal scale) or better using the ETDRS chart in one eye
- Subject at minimum with one eye with a natural, intact lens
- Subject who has a LOCS III score at baseline of P \< 1.0, C \< 2.0 and NO \< 2.0 in at least one eye
- Women in child bearing potential must have a negative pregnancy test
Exclusion
- Presence or history of any other malignancy (other than curatively treated basal cell or squamous cell carcinoma of the skin, in situ cervical carcinoma, or other surgically cured malignancy, without evidence of disease for \> 3 years
- Prior autologous or allogeneic transplants
- Prior treatment with palifermin, or other fibroblast or keratinocyte growth factors
- Receiving dialysis
- History of cataract surgery in both eyes
- Incapable of being responsive to mydriatic agents
- History of other ocular disease (e.g., macular degeneration, glaucoma, corneal disease) that would make assessment of visual status difficult
- Subject is scheduled to undergo cataract surgery
- Subject with any disease, that in the opinion of the ophthalmologist, could adversely effect the subject's vision during the course of the study
- Currently active oral mucositis infection
- Positive for HIV, hepatitis B or C
- Subject is unable or unwilling to follow with study procedures
- Subject is pregnant or is breast feeding
- Subject has not agreed to use adequate contraceptive precautions
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2012
Estimated Enrollment :
281 Patients enrolled
Trial Details
Trial ID
NCT00434161
Start Date
December 1 2006
End Date
May 1 2012
Last Update
March 30 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitatsklinikum Leipzig
Leipzig, Germany